STOCK TITAN
  1. Home
  2. Sec-filings
  3. MOLN
  4. [SCHEDULE 13G] Molecular Partners AG American SEC Filing

[SCHEDULE 13G] Molecular Partners AG American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock MOLN logo
MOLECULAR PARTNERS AG

NASDAQ:MOLN

MOLN Rankings

#4489 Ranked by Market Cap
N/A Ranked by Dividends

MOLN Latest News

Aug 25, 2025
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
Aug 21, 2025
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
Jun 22, 2025
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
Jun 11, 2025
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
Jun 10, 2025
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

MOLN Latest SEC Filings

Aug 25, 2025
[6-K] Molecular Partners AG American Current Report (Foreign Issuer)
Jun 25, 2025
[S-8] Molecular Partners AG American Employee Benefit Plan Registration

MOLN Stock Data

143.96M
36.86M
9.73%
0.07%
Biotechnology
Healthcare
Link
Switzerland
Schlieren